Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 8

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects

Dallal Bashi, Yahya H., Mairs, Rachel, Murtadha, Rand, Kett, Vicky · 2025 · Pharmaceutics

Abstract

This paper presents a comprehensive review of the current literature, clinical trials, and products approved for the delivery of antibiotics to the lungs. While there are many literature reports describing potential delivery systems, few of these have translated into marketed products. Key challenges remaining are the high doses required and, for powder formulations, the ability of the inhaler and powder combination to deliver the dose to the correct portion of the respiratory tract for maximum effect. Side effects, safety concerns, and disappointing clinical trial results remain barriers to regulatory approval. In this review, we describe some possible approaches to address these issues and highlight prospects in this area.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics17010111

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 220

  1. Pasteur, 2010, British Thoracic Society Guideline for Non-CF Bronchiectasis, Thorax, 65, 577, 10.1136/thx.2010.142778 · DOI · Paper page
  2. Patton, 2007, Inhaling Medicines: Delivering Drugs to the Body through the Lungs, Nat. Rev. Drug Discov., 6, 67, 10.1038/nrd2153 · DOI · Paper page
  3. Labiris, 2003, Pulmonary Drug Delivery. Part I: Physiological Factors Affecting Therapeutic Effectiveness of Aerosolized Medications, Br. J. Clin. Pharmacol., 56, 588, 10.1046/j.1365-2125.2003.01892.x · DOI · Paper page
  4. Agent, 2015, Inhaled Therapy in Cystic Fibrosis: Agents, Devices and Regimens, Breathe, 11, 111, 10.1183/20734735.021014 · DOI
  5. Dhand, 2018, The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas Aeruginosa Infection in Non-Cystic Fibrosis Bronchiectasis, J. Aerosol Med. Pulm. Drug Deliv., 31, 121, 10.1089/jamp.2017.1415 · DOI
  6. Sherrard, 2016, The Role of Anaerobic Bacteria in the Cystic Fibrosis Airway, Curr. Opin. Pulm. Med., 22, 637, 10.1097/MCP.0000000000000299 · DOI
  7. Sherrard, 2014, Antimicrobial Resistance in the Respiratory Microbiota of People with Cystic Fibrosis, Lancet, 384, 703, 10.1016/S0140-6736(14)61137-5 · DOI
  8. Elborn, 2016, Safety and Efficacy of Prolonged Levofloxacin Inhalation Solution (Apt-1026) Treatment for Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway Infection, J. Cyst. Fibros., 15, 634, 10.1016/j.jcf.2016.01.005 · DOI
  9. Maselli, D.J., Keyt, H., and Restrepo, M.I. (2017). Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. Int. J. Mol. Sci., 18. · DOI
  10. Yanagihara, 2002, Effect of Clarithromycin on Chronic Respiratory Infection Caused by Pseudomonas aeruginosa with Biofilm Formation in an Experimental Murine Model, J. Antimicrob. Chemother., 49, 867, 10.1093/jac/dkf013 · DOI
  11. Mah, 2001, Mechanisms of Biofilm Resistance to Antimicrobial Agents, Trends Microbiol., 9, 34, 10.1016/S0966-842X(00)01913-2 · DOI · Paper page
  12. Waters, 2015, Cystic Fibrosis Microbiology: Advances in Antimicrobial Therapy, J. Cyst. Fibros., 14, 551, 10.1016/j.jcf.2015.02.005 · DOI
  13. Pennelly, 2016, Biofilm Formation by Mycobacterium abscessus in a Lung Cavity, Am. J. Respir. Crit. Care Med., 193, 692, 10.1164/rccm.201508-1586IM · doi:10.1164/rccm.201508-1586im
  14. Uruén, C., Chopo-Escuin, G., Tommassen, J., Mainar-Jaime, R.C., and Arenas, J. (2021). Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance. Antibiotics, 10. · DOI · Paper page
  15. Guillaume, O., Butnarasu, C., Visentin, S., and Reimhult, E. (2022). Interplay between Biofilm Microenvironment and Pathogenicity of Pseudomonas aeruginosa in Cystic Fibrosis Lung Chronic Infection. Biofilm, 4. · DOI · Paper page
  16. Rukavina, Z., and Vani, Z. (2016). Current Trends in Development of Liposomes for Targeting Bacterial Biofilms. Pharmaceutics, 8. · DOI · Paper page
  17. Chakraborty, 2021, Biofilm Formation in the Lung Contributes to Virulence and Drug Tolerance of Mycobacterium tuberculosis, Nat. Commun., 12, 1606, 10.1038/s41467-021-21748-6 · DOI · Paper page
  18. Vandeplassche, E., Sass, A., Ostyn, L., Burmolle, M., Kragh, K.N., Bjarnsholt, T., Coenye, T., and Crabbé, A. (2020). Antibiotic Susceptibility of Cystic Fibrosis Lung Microbiome Members in a Multispecies Biofilm. Biofilm, 2. · DOI
  19. Sun, 2013, Biofilm-Associated Infections: Antibiotic Resistance and Novel Therapeutic Strategies, Future Microbiol., 8, 877, 10.2217/fmb.13.58 · DOI · Paper page
  20. Gao, 2020, Size and Charge Adaptive Clustered Nanoparticles Targeting the Biofilm Microenvironment for Chronic Lung Infection Management, ACS Nano, 14, 5686, 10.1021/acsnano.0c00269 · DOI · Paper page
  21. Bashi, 2024, Inhaled Dry Powder Liposomal Azithromycin for Treatment of Chronic Lower Respiratory Tract Infection, Int. J. Pharm., 653, 123841, 10.1016/j.ijpharm.2024.123841 · DOI
  22. Purushothaman, A.K., Natarajan, S., Panigrahi, T., and Nelson, E.J.R. (2024). Diagnosis and Treatment of Cystic Fibrosis in India: What Is at Stake for Developing Countries?. J. Biosci., 49. · DOI
  23. Ledger, 2024, Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People with Cystic Fibrosis, J. Infect. Dis., 320, e536, 10.1093/infdis/jiae051 · DOI
  24. Chandrasekaran, R., Mac Aogáin, M., Chalmers, J.D., Elborn, S.J., and Chotirmall, S.H. (2018). Geographic Variation in the Aetiology, Epidemiology and Microbiology of Bronchiectasis. BMC Pulm. Med., 18. · DOI · Paper page
  25. Chalmers, 2023, Bronchiectasis in Europe: Data on Disease Characteristics from the European Bronchiectasis Registry (EMBARC), Lancet Respir. Med., 11, 637, 10.1016/S2213-2600(23)00093-0 · DOI · Paper page
  26. Dean, S.G., Blakney, R.A., Ricotta, E.E., Chalmers, J.D., Kadri, S.S., Olivier, K.N., and Prevots, D.R. (2024). Bronchiectasis-Associated Infections and Outcomes in a Large, Geographically Diverse Electronic Health Record Cohort in the United States. BMC Pulm. Med., 24. · DOI
  27. King, 2002, Pharmacological Approaches to Discovery and Development of New Mucolytic Agents, Adv. Drug Deliv. Rev., 54, 1475, 10.1016/S0169-409X(02)00156-4 · DOI
  28. Rubin, 2009, Mucus, Phlegm, and Sputum in Cystic Fibrosis, Respir. Care, 54, 726, 10.4187/002013209790983269 · DOI
  29. Sanders, 2009, Extracellular Barriers in Respiratory Gene Therapy, Adv. Drug Deliv. Rev., 61, 115, 10.1016/j.addr.2008.09.011 · DOI · Paper page
  30. Daviskas, 2006, Hyperosmolar agents and clearance of mucus in the diseased airway, J. Aerosol Med.-Depos. Clear. Eff. Lung, 19, 100, 10.1089/jam.2006.19.100 · doi:10.1089/jam.2006.19.100
  31. Cone, 2009, Barrier Properties of Mucus, Adv. Drug Deliv. Rev., 61, 75, 10.1016/j.addr.2008.09.008 · DOI · Paper page
  32. Sigurdsson, 2013, Mucus as a Barrier to Lipophilic Drugs, Int. J. Pharm., 453, 56, 10.1016/j.ijpharm.2013.05.040 · DOI · Paper page
  33. Lai, 2009, Mucus-Penetrating Nanoparticles for Drug and Gene Delivery to Mucosal Tissues, Adv. Drug Del. Rev., 61, 158, 10.1016/j.addr.2008.11.002 · DOI · Paper page
  34. Ibrahim, 2011, Challenges and Advances in the Development of Inhalable Drug Formulations for Cystic Fibrosis Lung Disease, Expert Opin. Drug Deliv., 8, 451, 10.1517/17425247.2011.561310 · DOI
  35. Ensign, 2012, Mucus Penetrating Nanoparticles: Biophysical Tool and Method of Drug and Gene Delivery, Adv. Mater., 24, 3887, 10.1002/adma.201201800 · DOI · Paper page
  36. Conte, 2014, Improving the Efficacy of Inhaled Drugs in Cystic Fibrosis: Challenges and Emerging Drug Delivery Strategies, Adv. Drug Deliv. Rev., 75, 92, 10.1016/j.addr.2014.05.008 · DOI
  37. Ramphal, 1988, The Binding of Anti-Pseudomonal Antibiotics to Macromolecules from Cystic-Fibrosis Sputum, J. Antimicrob. Chemother., 22, 483, 10.1093/jac/22.4.483 · doi:10.1093/jac/22.4.483
  38. Hunt, 1995, Macromolecular Mechanisms of Sputum Inhibition of Tobramycin Activity Antimicrob, Agents Chemother., 39, 34, 10.1128/AAC.39.1.34 · DOI
  39. Loebinger, 2009, Mortality in Bronchiectasis: A Long-Term Study Assessing the Factors Influencing Survival, Eur. Respir. J., 34, 843, 10.1183/09031936.00003709 · DOI · Paper page
  40. Torres, 1991, Severe Community-Acquired Pneumonia—Epidemiology and Prognostic Factors, Am. Rev. Respir. Dis., 144, 312, 10.1164/ajrccm/144.2.312 · DOI · Paper page
  41. Soriano, 2007, Factors Associated with Lung Function Decline in Adult Patients with Stable Non-Cystic Fibrosis bronchiectasis, Chest, 132, 1565, 10.1378/chest.07-0490 · DOI · Paper page
  42. Poole, 2001, Multidrug Efflux Pumps and Antimicrobial Resistance in Pseudomonas aeruginosa and Related Organisms, J. Mol. Microbiol. Biotechnol., 3, 255
  43. Nguyen, 2023, In Vitro Susceptibility Patterns for Slowly Growing Non-Tuberculous Mycobacteria in the USA from 2018 to 2022, J. Antimicrob. Chemother., 78, 2849, 10.1093/jac/dkad317 · doi:10.1093/jac/dkad317
  44. Zhou, 2022, Global Prevalence of Non-Tuberculous Mycobacteria in Adults with Non-Cystic Fibrosis Bronchiectasis 2006–2021: A Systematic Review and Meta-Analysis, BMJ Open, 12, 10, 10.1136/bmjopen-2021-055672 · DOI
  45. Mathis, 2023, Epidemiological Trends in Non-Tuberculous Mycobacterial Infections in Patients with Cystic Fibrosis in Germany, Klin. Padiatr., 235, 118
  46. Duplancic, 2022, Non-Tuberculous Mycobacteria in Australians with Cystic Fibrosis: A National Survey, Respirology, 27, 77
  47. Domingo, 2020, Prevalence and Importance of Non-Tuberculous Mycobacteria in Adult Patients with Cystic Fibrosis in a Hospital in Madrid, Enferm. Infecc. Microbiol. Clin., 38, 323, 10.1016/j.eimc.2019.09.007 · DOI
  48. Eikani, M.S., Nugent, M., Poursina, A., Simpson, P., and Levy, H. (2018). Clinical Course and Significance of Nontuberculous Mycobacteria and Its Subtypes in Cystic Fibrosis. BMC Infect. Dis., 18. · DOI
  49. Mullen, 2024, Geographic Variation and Environmental Predictors of Nontuberculous Mycobacteria in Laboratory Surveillance, Virginia, USA, 2021–2023, Emerg. Infect. Dis., 30, 548, 10.3201/eid3003.231162 · doi:10.3201/eid3003.231162
  50. Corbett, 2023, Development of Prevalence and Incidence of Non-Tuberculous Mycobacteria in German Laboratories from 2016 to 2020, Emerg. Microbes Infect., 12, 2276342, 10.1080/22221751.2023.2276342 · doi:10.1080/22221751.2023.2276342
  51. Aulicino, A., Dinan, A.M., Miranda-CasoLuengo, A.A., Browne, J.A., Rue-Albrecht, K., MacHugh, D.E., and Loftus, B.J. (2015). High-Throughput Transcriptomics Reveals Common and Strain-Specific Responses of Human Macrophages to Infection with Mycobacterium abscessus Smooth and Rough variants. BMC Genom., 16. · DOI
  52. Daley, 2020, Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline, Clin. Infect. Dis., 71, 905, 10.1093/cid/ciaa1125 · DOI · Paper page
  53. Martiniano, 2020, Challenging Scenarios in Nontuberculous Mycobacterial Infection in Cystic Fibrosis, Pediatr. Pulmonol., 55, 521, 10.1002/ppul.24604 · DOI
  54. Logan, 2017, The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace, J. Infect. Dis., 215, S28, 10.1093/infdis/jiw282 · DOI · Paper page
  55. Saadh, 2022, The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis, Yale J. Biol. Med., 95, 495
  56. Narimisa, N., Keshtkar, A., Dadgar-Zankbar, L., Bostanghadiri, N., Far, Y.R., Shahroodian, S., Bialvaei, A.Z., and Razavi, S. (2024). Prevalence of Colistin Resistance in Clinical Isolates of Pseudomonas aeruginosa: A Systematic Review and Meta-Analysis. Front. Microbiol., 15. · DOI
  57. Ma, J., Song, X., Li, M., Yu, Z., Cheng, W., Yu, Z., Zhang, W., Zhang, Y., Shen, A., and Sun, H. (2023). Global Spread of Carbapenem-Resistant Enterobacteriaceae: Epidemiological Features, Resistance Mechanisms, Detection and Therapy. Microbiol. Res., 266. · DOI · Paper page
  58. Bonaiti, G., Pesci, A., Marruchella, A., Lapadula, G., Gori, A., and Aliberti, S. (2015). Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis. BioMed Res. Int., 2015. · DOI
  59. Hill, 2019, British Thoracic Society Guideline for Bronchiectasis in Adults, Thorax, 74, 1
  60. Hill, 2022, British Thoracic Society Quality Standard for Clinically Significant Bronchiectasis in Adults 2022, BMJ Open Respir. Res., 9, e001369, 10.1136/bmjresp-2022-001369 · doi:10.1136/bmjresp-2022-001369
  61. Axson, 2018, Nontuberculous Mycobacterial Disease Managed within UK Primary Care, 2006–2016, Eur. J. Clin. Microbiol. Infect. Dis., 37, 1795, 10.1007/s10096-018-3315-6 · DOI
  62. Bents, S.J., Mercaldo, R.A., Powell, C., Henkle, E., Marras, T.K., and Prevots, D.R. (2024). Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) Incidence Trends in the United States, 2010–2019. BMC Infect. Dis., 24. · DOI
  63. Wang, 2024, Nontuberculous Mycobacterial Pulmonary Disease Added Burden to COPD and Bronchiectasis in Japan, ERJ Open Res., 10, 00911, 10.1183/23120541.00911-2023 · doi:10.1183/23120541.00911-2023
  64. Bosteels, 2024, Growing from Common Ground: Nontuberculous Mycobacteria and Bronchiectasis, Eur. Respir. Rev., 33, 240058, 10.1183/16000617.0058-2024 · DOI
  65. Pedersen, 2024, Nationwide Increasing Incidence of Nontuberculous Mycobacterial Diseases among Adults in Denmark Eighteen Years of Follow-Up, Chest, 166, 271, 10.1016/j.chest.2024.03.023 · doi:10.1016/j.chest.2024.03.023
  66. Wang, 2024, Clinical Predictors of Nontuberculous Mycobacteria Lung Disease and Coisolates of Potential Pathogenic Microorganisms in Noncystic Fibrosis Bronchiectasis, Open Forum Infect. Dis., 11, ofae427, 10.1093/ofid/ofae427 · DOI
  67. Elborn, 2021, Management of Chronic Pseudomonas aeruginosa Infection with Inhaled Levofloxacin in People with Cystic Fibrosis, Future Microbiol., 16, 1087, 10.2217/fmb-2021-0150 · DOI
  68. Mogayzel, 2014, Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection, Ann. Am. Thorac. Soc., 11, 1640, 10.1513/AnnalsATS.201404-166OC · DOI · Paper page
  69. Clancy, 2013, Phase II Studies of Nebulised Arikace in CF Patients with Pseudomonas aeruginosa Infection, Thorax, 68, 818, 10.1136/thoraxjnl-2012-202230 · DOI · Paper page
  70. Elborn, 2016, Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients with Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis, Clin. Ther., 38, 2204, 10.1016/j.clinthera.2016.08.014 · DOI
  71. Bilton, 2006, Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis, Chest, 130, 1503, 10.1378/chest.130.5.1503 · doi:10.1378/chest.130.5.1503
  72. Barker, 2014, Aztreonam for Inhalation Solution in Patients with Non-Cystic Fibrosis Bronchiectasis (AIR-BX1 and AIR-BX2): Two Randomised Double-Blind, Placebo-Controlled Phase 3 Trials, Lancet Respir. Med., 2, 738, 10.1016/S2213-2600(14)70165-1 · DOI · Paper page
  73. Haworth, 2014, Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection, Am. J. Respir. Crit. Care Med., 189, 975, 10.1164/rccm.201312-2208OC · DOI · Paper page
  74. Tejada, 2021, Inhaled Antibiotics for Treatment of Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and meta-Analysis, Eur. J. Intern. Med., 90, 77, 10.1016/j.ejim.2021.04.009 · doi:10.1016/j.ejim.2021.04.009
  75. Haworth, 2021, RCT Abstract—The efficacy and Safety of Colistimethate Sodium Delivered via the I-Neb in Bronchiectasis: The PROMIS-I Randomized Controlled Trial, Eur. Respir. J., 58, RCT4267
  76. Golpe, 2022, Inhaled Colistimethate Sodium in the Management of Patients with Bronchiectasis Infected by Pseudomonas aeruginosa: A Narrative Review of Current Evidence, Infect. Drug Resist., 15, 7271, 10.2147/IDR.S318173 · DOI
  77. Wong, 2023, Randomized Clinical Trials of Inhaled Antibiotics in Bronchiectasis Cause for Optimism?, Chest, 163, 3, 10.1016/j.chest.2022.09.003 · doi:10.1016/j.chest.2022.09.003
  78. Dolovich, 2005, Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines, Chest, 127, 335, 10.1378/chest.127.1.335 · DOI · Paper page
  79. Tiddens, 2014, Inhaled Antibiotics: Dry or Wet?, Eur. Respir. J., 44, 1308, 10.1183/09031936.00090314 · doi:10.1183/09031936.00090314
  80. Wenzler, 2016, Inhaled Antibiotics for Gram-Negative Respiratory Infections, Clin. Microbiol. Rev., 29, 581, 10.1128/CMR.00101-15 · DOI
  81. Viehman, 2014, Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections, Drugs, 74, 1315, 10.1007/s40265-014-0267-8 · DOI · Paper page
  82. McKinzie, 2019, Off-Label Use of Intravenous Antimicrobials for Inhalation in Patients with Cystic Fibrosis, Pediatr. Pulmonol., 54, S27, 10.1002/ppul.24511 · doi:10.1002/ppul.24511
  83. Nielsen, 2022, Use of Inhaled Antibiotics among Danish Patients with Cystic Fibrosis, Pediatr. Pulmonol., 57, 1726, 10.1002/ppul.25942 · DOI
  84. Bos, 2016, Daily Observations of Nebuliser Use and Technique (DONUT) in Children with Cystic Fibrosis, J. Cyst. Fibros., 15, 645, 10.1016/j.jcf.2016.03.005 · DOI
  85. Davison, 2023, Patient Attitudes to Nebulised Antibiotics in the Treatment of Bronchiectasis: A Mixed-Methods Study, ERJ Open Res., 9, 9, 10.1183/23120541.00735-2022 · DOI
  86. Stanford, 2023, Nebuliser Systems for Drug Delivery in Cystic Fibrosis, Cochrane Database Syst. Rev., 11, Cd007639
  87. Banaschewski, B., and Hofmann, T. (2019). Inhaled Antibiotics for Mycobacterial Lung Disease. Pharmaceutics, 11. · DOI
  88. Hou, 2015, Practical, Regulatory and Clinical Considerations for Development of Inhalation Drug Products, Asian J. Pharm. Sci., 10, 490, 10.1016/j.ajps.2015.08.008 · DOI
  89. 2015, Dry Powder Inhalers and the Right Things to Remember: A Concept Review, Multidiscip. Respir. Med., 10, 13, 10.1186/s40248-015-0012-5 · DOI
  90. Greenberg, 2016, Treatment Satisfaction in Cystic Fibrosis: Early Patient Experience with Tobramycin Inhalation Powder, Patient Prefer. Adherence, 10, 2163, 10.2147/PPA.S102234 · DOI
  91. Fiel, 2022, The Use of Tobramycin for Pseudomonas aeruginosa: A Review, Expert Rev. Respir. Med., 16, 503, 10.1080/17476348.2022.2057951 · DOI
  92. Terpstra, 2022, The BATTLE Study: Effects of Long-Term Tobramycin Inhalation Solution (TIS) Once Daily on Exacerbation Rate in Patients with Non-Cystic Fibrosis Bronchiectasis. Study Protocol of a Double Blind, Randomized, Placebo-Controlled Trial: Study Protocol, Contemp. Clin. Trials Commun., 30, 101045, 10.1016/j.conctc.2022.101045 · DOI
  93. Cameron, 2022, Treatment Preference among People with Cystic Fibrosis the Importance of Reducing Treatment Burden, Chest, 162, 1241, 10.1016/j.chest.2022.07.008 · DOI
  94. Mohamed, 2016, Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections, Patient, 9, 59, 10.1007/s40271-015-0124-1 · DOI
  95. Pilcer, 2010, Formulation Strategy and Use of Excipients in Pulmonary Drug Delivery, Int. J. Pharm., 392, 1, 10.1016/j.ijpharm.2010.03.017 · DOI · Paper page
  96. Terzano, 2008, Dry Powder Inhalers and the Risk of Error, Respiration, 75, 14, 10.1159/000111774 · DOI
  97. Capstick, 2024, Demystifying Dry Powder Inhaler Resistance with Relevance to Optimal Patient Care, Clin. Drug Investig., 44, 109, 10.1007/s40261-023-01330-2 · doi:10.1007/s40261-023-01330-2
  98. Sarinas, 1998, Inspiratory Flow Rate and Dynamic Lung Function in Cystic Fibrosis and Chronic Obstructive Lung Diseases, Chest, 114, 988, 10.1378/chest.114.4.988 · doi:10.1378/chest.114.4.988
  99. Gambazza, 2023, Adherence to Inhaled Antibiotics in People with Cystic Fibrosis: Insights from a Virtual Patient Advisory Board, Expert Rev. Respir. Med., 17, 961, 10.1080/17476348.2023.2267427 · doi:10.1080/17476348.2023.2267427
  100. Manfred, 2024, Considerations for the Use of Inhaled Antibiotics for Pseudomonas aeruginosa in People with Cystic Fibrosis Receiving CFTR Modulator Therapy, BMJ Open Respir. Res., 11, e002049, 10.1136/bmjresp-2023-002049 · DOI
  101. Conole, 2014, Colistimethate Sodium Dry Powder for Inhalation: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis, Drugs, 74, 377, 10.1007/s40265-014-0181-0 · DOI
  102. Konstan, 2011, Tobramycin Inhalation Powder for P. aeruginosa Infection in Cystic Fibrosis: The Evolve Trial, Pediatr. Pulmonol., 46, 230, 10.1002/ppul.21356 · DOI · Paper page
  103. Andremont, 2000, Targeted Delivery of Antibiotics Using Liposomes and Nanoparticles: Research and Applications, Int. J. Antimicrob. Agents, 13, 155, 10.1016/S0924-8579(99)00121-1 · DOI · Paper page
  104. Chalmers, 2021, Liposomal Drug Delivery to Manage Nontuberculous Mycobacterial Pulmonary Disease and Other Chronic Lung Infections, Eur. Respir. Rev., 30, 210010, 10.1183/16000617.0010-2021 · DOI
  105. Griffith, 2018, Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT), Am Am. J. Respir. Crit. Care Med., 198, 1559, 10.1164/rccm.201807-1318OC · DOI · Paper page
  106. Shirley, 2019, Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease, Drugs, 79, 555, 10.1007/s40265-019-01095-z · DOI
  107. Takao, 2023, A Case of Drug-Induced Organizing Pneumonia Caused by Amikacin Liposome Inhalation Suspension, J. Infect. Chemother., 29, 806, 10.1016/j.jiac.2023.04.013 · doi:10.1016/j.jiac.2023.04.013
  108. Bilton, 2021, Long-Term Amikacin Liposome Inhalation Suspension in Cystic Fibrosis Patients with Chronic P. aeruginosa Infection, J. Cyst. Fibros., 20, 1010, 10.1016/j.jcf.2021.05.013 · DOI
  109. Serisier, 2013, Inhaled, Dual Release Liposomal Ciprofloxacin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-2): A Randomised, Double-Blind, Placebo-Controlled Trial, Thorax, 68, 812, 10.1136/thoraxjnl-2013-203207 · DOI · Paper page
  110. Haworth, 2019, Inhaled Liposomal Ciprofloxacin in Patients with Non-Cystic Fibrosis Bronchiectasis and Chronic Lung Infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): Two Phase 3, Randomised Controlled Trials, Lancet Respir. Med., 7, 213, 10.1016/S2213-2600(18)30427-2 · DOI · Paper page
  111. Aksamit, 2018, Respire 1: A Phase III Placebo-Controlled Randomised Trial of Ciprofloxacin Dry Powder for Inhalation in Non-Cystic Fibrosis Bronchiectasis, Eur. Respir. J., 51, 1702052, 10.1183/13993003.02053-2017 · DOI · Paper page
  112. Aksamit, 2017, The Respire Trials: Two Phase III, Randomized, Multicentre, Placebo-Controlled Trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in Non-Cystic Fibrosis Bronchiectasis, Contemp. Clin. Trials, 58, 78, 10.1016/j.cct.2017.05.007 · DOI
  113. Aksamit, 2018, Respire 2: A Phase III Placebo-Controlled Randomised Trial of Ciprofloxacin Dry Powder for Inhalation in Non-Cystic Fibrosis Bronchiectasis, Eur. Respir. Rev., 51, 1702053, 10.1183/13993003.02053-2017 · DOI · Paper page
  114. Waterer, 2020, Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: A New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 64, e0177619, 10.1128/AAC.01776-19 · doi:10.1128/aac.01776-19
  115. Dale, 2018, Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment, Antimicrob. Agents Chemother., 62, e0049018, 10.1128/AAC.00490-18 · DOI
  116. Movia, D., and Prina-Mello, A. (2020). Preclinical Development of Orally Inhaled Drugs (OIDs)-Are Animal Models Predictive or Shall We Move Towards In Vitro Non-Animal Models?. Animals, 10. · DOI
  117. Chorepsima, 2018, Spotlight on Inhaled Ciprofloxacin and Its Potential in the Treatment of Non-Cystic Fibrosis Bronchiectasis, Drug Des. Dev. Ther., 12, 4059, 10.2147/DDDT.S168014 · doi:10.2147/dddt.s168014
  118. Sibila, 2022, Heterogeneity of Treatment Response in Bronchiectasis Clinical Trials, Eur. Respir. J., 59, 2100777, 10.1183/13993003.00777-2021 · DOI
  119. Chang, 2022, European Respiratory Society Statement for Defining Respiratory Exacerbations in Children and Adolescents with Bronchiectasis for Clinical Trials, Eur. Respir. J., 60, 2200300, 10.1183/13993003.00300-2022 · doi:10.1183/13993003.00300-2022
  120. Fauconnier, A. (2019). Phage Therapy Regulation: From Night to Dawn. Viruses, 11. · DOI
  121. Dedrick, 2023, Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease, Clin. Infect. Dis., 76, 103, 10.1093/cid/ciac453 · DOI · Paper page
  122. Wright, 2009, A controlled Clinical trial Of a Therapeutic Bacteriophage Preparation in Chronic Otitis Due to Antibiotic-Resistant Pseudomonas aeruginosa; a Preliminary Report of Efficacy, Clin. Otolaryngol., 34, 349, 10.1111/j.1749-4486.2009.01973.x · DOI · Paper page
  123. Pelfrene, 2016, Bacteriophage Therapy: A Regulatory Perspective, J. Antimicrob. Chemother., 71, 2071, 10.1093/jac/dkw083 · DOI
  124. Perea, 2021, Bacteriophages Immunomodulate the Response of Monocytes, Exp. Biol. Med., 246, 1263, 10.1177/1535370221995154 · DOI
  125. Muniesa, 2015, Transfer of Antibiotic-Resistance Genes via Phage-Related Mobile Elements, Plasmid, 79, 1, 10.1016/j.plasmid.2015.01.001 · DOI · Paper page
  126. Isles, M.P. (2022). Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety. Front. Pharmacol., 12. · DOI
  127. Lipsa, D., Magrì, D., Della Camera, G., La Spina, R., Cella, C., Garmendia-Aguirre, I., Mehn, D., Ruiz-Moreno, A., Fumagalli, F., and Calzolai, L. (2023). Differences in Physico-Chemical Properties and Immunological Response in Nanosimilar Complex Drugs: The Case of Liposomal Doxorubicin. Int. J. Mol. Sci., 24. · DOI
  128. Demetzos, 2024, Nanosimilars: A Scientific or A Regulatory Debate?, AAPS J., 26, 74, 10.1208/s12248-024-00942-6 · doi:10.1208/s12248-024-00942-6
  129. Hannon, G., and Prina-Mello, A. (2021). Endotoxin Contamination of Engineered Nanomaterials: Overcoming the Hurdles Associated with Endotoxin Testing. WIREs Nanomed. Nanobiotechnol., 13. · DOI
  130. Chavez, 2023, Spatial Epidemiologic Analysis and Risk Factors for Nontuberculous Mycobacteria Infections, Missouri, USA, 2008–2019, Emerg. Infect. Dis., 29, 1540
  131. Gao, 2024, A phase 4 Multicentre, 2x2 Factorial Randomised, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy and Safety of Tobramycin Inhalation Solution for Pseudomonas aeruginosa Eradication in Bronchiectasis: Erase, ERJ Open Res., 10, 00938, 10.1183/23120541.00938-2023 · doi:10.1183/23120541.00938-2023
  132. Sangiovanni, 2021, Inhaled Tobramycin for Chronic Infection with Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and Meta-Analysis, Respir. Med., 176, 106283, 10.1016/j.rmed.2020.106283 · doi:10.1016/j.rmed.2020.106283
  133. Motta, 2024, Comparative Microbiome Analysis in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis, Respir. Res., 25, 211, 10.1186/s12931-024-02835-w · DOI
  134. Shimizu, 2015, Pathogens in COPD Exacerbations Identified by Comprehensive Real-Time PCR Plus Older Methods, Int. J. Chron. Obstruct. Pulmon. Dis., 10, 2009, 10.2147/COPD.S82752 · DOI
  135. Sibila, 2017, The Respiratory Threat Posed by Multidrug Resistant Gram-Negative Bacteria, Respirology, 22, 1288, 10.1111/resp.13115 · DOI
  136. Erol, 2018, Effect of Sputum Bacteriology on the Prognosis of Patients with Acute Exacerbations of Bronchiectasis in the Intensive Care Unit, Eurasian J. Pulmonol., 20, 85
  137. Tacconelli, 2018, Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis, Lancet Infect. Dis., 18, 318, 10.1016/S1473-3099(17)30753-3 · DOI · Paper page
  138. Marner, 2023, Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients, Microbiol. Spectr., 11, e0443722, 10.1128/spectrum.04437-22 · DOI
  139. Abichabki, N., Gaspar, G.G., Zacharias, L.V., Pocente, R.H.C., Lima, D., de Freitas, N.A.B., Brancini, G.T.P., Moreira, N.C., Braga, G.U.L., and Bellissimo-Rodrigues, F. (2024). In Vitro Synergistic Activity of Rifampicin Combined with Minimal Effective Antibiotic Concentration (MEAC) of Polymyxin B Against Extensively Drug-Resistant, Carbapenem-, and Polymyxin B-Resistant Klebsiella pneumoniae Clinical Isolates. Curr. Microbiol., 81. · DOI
  140. Chaudhary, M., Kumar, D., Meena, D.S., Midha, N.K., Bohra, G.K., Tak, V., Samantaray, S., Kaur, N., Neetha, T.R., and Mohammed, S. (2024). Effectiveness of Various Sulbactam-Based Combination Antibiotic Therapy in the Management of Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter Baumannii in a Tertiary Care Health Centre. Indian J. Med. Microbiol., 52. · DOI
  141. Siddiqui, 2024, Scrutinizing the Effect of Additive and Synergistic Antibiotics against Carbapenem-Resistant Pseudomonas aeruginosa, Open Chem., 22, 20240074, 10.1515/chem-2024-0074 · DOI
  142. Yang, Q., Le, S., Zhu, T., and Wu, N. (2023). Regulations of Phage Therapy Across the World. Front. Microbiol., 14. · DOI · Paper page
  143. Zasloff, 2002, Antimicrobial Peptides of Multicellular Organisms, Nature, 415, 389, 10.1038/415389a · DOI · Paper page
  144. Antunes, B., Zanchi, C., Johnston, P.R., Maron, B., Witzany, C., Regoes, R.R., Hayouka, Z., and Rolff, J. (2024). The Evolution of Antimicrobial Peptide Resistance in Pseudomonas aeruginosa Is Severely Constrained by Random Peptide Mixtures. PLoS Biol., 22. · DOI
  145. Flint, R., Laucirica, D.R., Chan, H.K., Chang, B.J., Stick, S.M., and Kicic, A. (2023). Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization. Cells, 12. · doi:10.3390/cells12162057
  146. Luscher, 2023, Personalized Aerosolised Bacteriophage Treatment of a Chronic Lung Infection Due to Multidrug-Resistant Pseudomonas aeruginosa, Nat. Commun., 14, 3629, 10.1038/s41467-023-39370-z · doi:10.1038/s41467-023-39370-z
  147. Chang, 2022, The Effects of Different Doses of Inhaled Bacteriophage Therapy for Pseudomonas aeruginosa Pulmonary Infections in Mice, Clin. Microbiol. Infect., 28, 983, 10.1016/j.cmi.2022.01.006 · DOI
  148. Eiselt, 2024, Phage Therapy in Lung Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa A Literature Review, Eur. J. Microbiol. Immunol., 14, 1, 10.1556/1886.2023.00060 · DOI
  149. Rahman, M.U., Wang, W., Sun, Q., Shah, J.A., Li, C., Sun, Y., Li, Y., Zhang, B., Chen, W., and Wang, S. (2021). Endolysin, a Promising Solution against Antimicrobial Resistance. Antibiotics, 10. · DOI · Paper page
  150. Faltus, T. (2024). The Medicinal Phage-Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation. Viruses, 16. · DOI
  151. Cholo, 2012, Clofazimine: Current Status and Future Prospects, J. Pharm. Pharmacol., 67, 290
  152. Nix, 2004, Pharmacokinetics and Relative Bioavailability of Clofazimine in Relation to Food, Orange Juice and Antacid, Tuberculosis, 84, 365, 10.1016/j.tube.2004.04.001 · doi:10.1016/j.tube.2004.04.001
  153. Valinetz, 2020, Novel Administration of Clofazimine for the Treatment of Mycobacterium avium Infection, Open Forum Infect. Dis., 7, ofaa183, 10.1093/ofid/ofaa183 · doi:10.1093/ofid/ofaa183
  154. Kunkel, 2023, Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection, Antimicrob. Agents Chemother., 67, e0114422, 10.1128/aac.01144-22 · doi:10.1128/aac.01144-22
  155. Banaschewski, 2019, Clofazimine Inhalation Suspension for the Aerosol Treatment of Pulmonary Nontuberculous Mycobacterial Infections, J. Cyst. Fibros., 18, 714, 10.1016/j.jcf.2019.05.013 · DOI
  156. Floto, 2016, US Cystic Fibrosis Foundation and European Cystic Fibrosis Society Consensus Recommendations for the Management of Non-Tuberculous Mycobacteria in Individuals with Cystic Fibrosis, Thorax, 71, i1, 10.1136/thoraxjnl-2015-207360 · DOI · Paper page
  157. Oh, 2014, Novel Drug Combination for Mycobacterium abscessus Disease Therapy Identified in a Drosophila Infection Model, J. Antimicrob. Chemother., 69, 1599, 10.1093/jac/dku024 · DOI
  158. Aznar, 2018, Safety and Effectiveness of Clofazimine in Nontuberculous Mycobacterial Lung Disease, Can. J. Respir. Crit. Care Sleep Med., 2, 72
  159. Martiniano, 2017, Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection, Chest, 152, 800, 10.1016/j.chest.2017.04.175 · DOI
  160. Ausina, 1986, In Vitro Activity of Clofazimine against Rapidly Growing Nonchromogenic Mycobacteria, Antimicrob. Agents Chemother., 29, 951, 10.1128/AAC.29.5.951 · doi:10.1128/aac.29.5.951
  161. Shen, 2010, High Efficacy of Clofazimine and Its Synergistic Effect with Amikacin against Rapidly Growing Mycobacteria, Int. J. Antimicrob. Agents, 35, 400, 10.1016/j.ijantimicag.2009.12.008 · DOI
  162. Brunaugh, 2022, Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection, Antimicrob. Agents Chemother., 66, e0018622, 10.1128/aac.00186-22 · DOI
  163. McGuffin, 2017, Clofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche, Open Forum Infect. Dis., 4, ofx147, 10.1093/ofid/ofx147 · DOI
  164. Singh, 2014, In Vitro Evaluation of a New Drug Combination against Clinical Isolates Belonging to the Mycobacterium abscessus Complex, Clin. Microbiol. Infect., 20, O1124, 10.1111/1469-0691.12780 · DOI
  165. Ferro, 2016, Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin, Antimicrob. Agents Chemother., 60, 1097, 10.1128/AAC.02615-15 · DOI
  166. Pfaeffle, 2021, Clofazimine for Treatment of Multidrug-Resistant Non-Tuberculous Mycobacteria, Pulm. Pharmacol. Ther., 70, 102058, 10.1016/j.pupt.2021.102058 · doi:10.1016/j.pupt.2021.102058
  167. Grobbelaar, 2019, Evolution of Rifampicin Treatment for Tuberculosis, Infect. Genet. Evol., 74, 103937, 10.1016/j.meegid.2019.103937 · doi:10.1016/j.meegid.2019.103937
  168. Kim, H.J., Lee, J.S., Kwak, N., Cho, J., Lee, C.H., Han, S.K., and Yim, J.J. (2019). Role of Ethambutol and Rifampicin in the Treatment of Mycobacterium avium Complex Pulmonary Disease. BMC Pulm. Med., 19. · DOI
  169. Hou, W., Nsengimana, B., Yan, C., Nashan, B., and Han, S. (2022). Involvement of Endoplasmic Reticulum Stress in Rifampicin-Induced Liver Injury. Front. Pharmacol., 13. · DOI
  170. Yazdanyar, 2019, KITTEN Following CAT on the Long-Term Use of Rifampicin in Hidradenitis Suppurativa and Effectiveness of Oral Contraceptives, Br. J. Dermatol., 181, 225, 10.1111/bjd.17900 · doi:10.1111/bjd.17900
  171. Harder, 1996, Clinically Important Drug Interactions with Anticoagulants—An Update, Clin. Pharmacokinet., 30, 416, 10.2165/00003088-199630060-00002 · DOI · Paper page
  172. Maartens, 2009, Effectiveness and Safety of Antiretrovirals with Rifampicin: Crucial Issues for High-Burden Countries, Antivir. Ther., 14, 1039, 10.3851/IMP1455 · doi:10.3851/imp1455
  173. Khadka, 2024, The Quest to Deliver High-Dose Rifampicin: Can the Inhaled Approach help?, Expert Opin. Drug Deliv., 21, 31, 10.1080/17425247.2024.2301931 · DOI
  174. Maviglia, 2009, Role of Old Antibiotics in Multidrug Resistant Bacterial Infections, Curr. Drug Targets, 10, 895, 10.2174/138945009789108846 · doi:10.2174/138945009789108846
  175. Khadka, 2023, A Review of Formulations and Preclinical Studies of Inhaled Rifampicin for Its Clinical Translation, Drug Deliv. Transl. Res., 13, 1246, 10.1007/s13346-022-01238-y · DOI
  176. Fohner, 2017, PharmGKB Summary: Macrolide Antibiotic Pathway, Pharmacokinetics/Pharmacodynamics, Pharmacogenet. Genom., 27, 164, 10.1097/FPC.0000000000000270 · DOI
  177. Idris, 2009, Azithromycin Therapy for Neutrophilic Airways Disease: Myth or Magic?, Thorax, 64, 186, 10.1136/thx.2008.103192 · DOI
  178. Nagai, 1991, Long-Term Low-Dose Administration of Erythromycin to Patients with Diffuse Panbronchiolitis, Respiration, 58, 145, 10.1159/000195915 · DOI · Paper page
  179. Nalca, 2006, Quorum-Sensing Antagonistic Activities of Azithromycin in Pseudomonas aeruginosa PAO1:: A Global Approach, Antimicrob. Agents Chemother., 50, 1680, 10.1128/AAC.50.5.1680-1688.2006 · DOI · Paper page
  180. Ichimiya, 1996, The Influence of Azithromycin on the Biofilm Formation of Pseudomonas aeruginosa in vitro, Chemotherapy, 42, 186, 10.1159/000239440 · DOI
  181. Gladue, 1989, In Vitro and In Vivo Uptake of Azithromycin (cp-62,993) by Phagocytic-Cells—Possible Mechanism of Delivery and Release at Sites of Infection, Antimicrob. Agents Chemother., 33, 277, 10.1128/AAC.33.3.277 · doi:10.1128/aac.33.3.277
  182. Ray, 2012, Azithromycin and the Risk of Cardiovascular Death, N. Engl. J. Med., 366, 1881, 10.1056/NEJMoa1003833 · DOI · Paper page
  183. Martinez, 2015, Clinical and Histologic Features of Azithromycin-Induced Liver Injury, Clin. Gastroenterol. Hepatol., 13, 369, 10.1016/j.cgh.2014.07.054 · DOI
  184. Ress, 2000, Irreversible Sensorineural Hearing Loss as a Result of Azithromycin Ototoxicity—A Case Report, Ann. Otol. Rhinol. Laryngol., 109, 435, 10.1177/000348940010900416 · DOI
  185. Riedel, 2019, Evaluation of Apramycin against Spectinomycin-Resistant and -Susceptible Strains of Neisseria gonorrhoeae, J. Antimicrob. Chemother., 74, 1311, 10.1093/jac/dkz012 · DOI
  186. Moore, 2018, Antimycobacterial Activity of Veterinary Antibiotics (Apramycin and Framycetin) against Mycobacterium abscessus: Implication for Patients with Cystic Fibrosis, Int. J. Mycobacteriol., 7, 265, 10.4103/ijmy.ijmy_73_18 · doi:10.4103/ijmy.ijmy_73_18
  187. Selchow, 2022, Apramycin Overcomes the Inherent Lack of Antimicrobial Bactericidal Activity in Mycobacterium abscessus, Antimicrob. Agents Chemother., 66, e0151021, 10.1128/aac.01510-21 · DOI
  188. Di Bonaventura, G., Lupetti, V., Verginelli, F., Giancristofaro, S., Barbieri, R., Gherardi, G., and Pompilio, A. (2022). Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity Against Pseudomonas aeruginosa from Cystic Fibrosis Patients. Front. Microbiol., 12. · doi:10.3389/fmicb.2021.801152
  189. Juhas, 2019, In Vitro Activity of Apramycin Against Multidrug-, Carbapenem- and Aminoglycoside-Resistant Enterobacteriaceae and Acinetobacter baumannii, J. Antimicrob. Chemother., 74, 944, 10.1093/jac/dky546 · DOI
  190. Truelson, 2018, Evaluation of Apramycin Activity against Methicillin-Resistant, Methicillin-Sensitive, and Vancomycin-Intermediate Staphylococcus aureus Clinical Isolates, Diagn. Microbiol. Infect. Dis., 92, 168, 10.1016/j.diagmicrobio.2018.05.018 · doi:10.1016/j.diagmicrobio.2018.05.018
  191. Galani, 2024, In Vitro Activity of Apramycin (EBL-1003) in Combination with Colistin, Meropenem, Minocycline or Sulbactam against XDR/PDR Acinetobacter baumannii Isolates from Greece, J. Antimicrob. Chemother., 79, 1101, 10.1093/jac/dkae077 · doi:10.1093/jac/dkae077
  192. Atlas, 2023, In Vitro Activity of Novel Apramycin-Dextran Nanoparticles and Free Apramycin against Selected Dutch and Pakistani Klebsiella Pneumonia Isolates, Heliyon, 9, e22821, 10.1016/j.heliyon.2023.e22821 · DOI
  193. Meyer, 2014, In Vivo Efficacy of Apramycin in Murine Infection Models, Antimicrob. Agents Chemother., 58, 6938, 10.1128/AAC.03239-14 · doi:10.1128/aac.03239-14
  194. Becker, 2021, Efficacy of EBL-1003 (Apramycin) against Acinetobacter baumannii Lung Infections in Mice, Clin. Microbiol. Infect., 27, 1315, 10.1016/j.cmi.2020.12.004 · DOI
  195. Zhao, 2022, Population Pharmacokinetics of Apramycin from First-in-Human Plasma and Urine Data to Support Prediction of Efficacious Dose, J. Antimicrob. Chemother., 77, 2718, 10.1093/jac/dkac225 · doi:10.1093/jac/dkac225
  196. Butler, 2020, Antibiotics in the Clinical Pipeline in October 2019, J. Antibiot., 73, 329, 10.1038/s41429-020-0291-8 · DOI · Paper page
  197. Plattner, M., Gysin, M., Haldimann, K., Becker, K., and Hobbie, S.N. (2020). Epidemiologic, Phenotypic, and Structural Characterization of Aminoglycoside-Resistance Gene aac(3)-IV. Int. J. Mol. Sci., 21. · DOI
  198. Sonousi, 2021, An Advanced Apralog with Increased in Vitro and in Vivo Activity toward Gram-Negative Pathogens and Reduced ex vivo Cochleotoxicity, Chemmedchem, 16, 335, 10.1002/cmdc.202000726 · doi:10.1002/cmdc.202000726
  199. Hughes, 2022, Translational in Vitro and in Vivo PKPD Modelling for Apramycin against Gram-Negative Lung Pathogens to Facilitate Prediction of Human Efficacious Dose in Pneumonia, Clin. Microbiol. Infect., 28, 1367, 10.1016/j.cmi.2022.05.003 · doi:10.1016/j.cmi.2022.05.003
  200. Gysin, 2022, Apramycin Susceptibility of Multidrug-Resistant Gram-Negative Blood Culture Isolates in Five Countries in Southeast Asia, Int. J. Antimicrob. Agents, 60, 106659, 10.1016/j.ijantimicag.2022.106659 · doi:10.1016/j.ijantimicag.2022.106659

200 of 220 shown

Cited by

See all 8

Metadata

Authors
Dallal Bashi, Y. H., Mairs, R., Murtadha, R., & Kett, V.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2025-01-15
Volume
17
Issue
1
Pages
111
ISSN
1999-4923
Cited by
8
References
3
Language
en
Funders
Northern Ireland Department for the Economy studentship

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects. https://app.cochat.ai/papers/10.3390/pharmaceutics17010111
The paper
Dallal Bashi, Y. H., Mairs, R., Murtadha, R., & Kett, V. (2025). Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects. Pharmaceutics. https://doi.org/10.3390/pharmaceutics17010111

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.